Injective: down on the short term, up in the long run

Jan 31

I wouldn't consider buying Injective at the moment. The price surged sharply from $6 to $40, and a pullback after such a steep increase is only logical. The presence of a yellow horizontal line above two peaks suggests an upcoming downtrend, which indeed occurred. While the fundamentals of Injective are sound, there's a possibility it could experience a further $10 drop in a corrective move. Following this consolidation, it might find its way back up, and in that upward trajectory, it's likely to surpass its all-time high (ATH) of $45. From there, it's expected to reach at least $66.9. However, predicting the new ATH depends on market conditions, and it's challenging to foresee when an upward trend will halt.